Injectable lipolysis is a non-surgical method of targeted fat-cell dissolution using deoxycholate (deoxycholic acid). It is the same type of molecule our body uses when digesting fats; however, when injected locally into the subcutaneous tissue, deoxycholate damages fat-cell membranes. The body then clears the cell debris, and the volume of fat in the treated area gradually decreases. In the U.S., this approach is approved for the area under the chin under the name Kybella; in Europe (including Slovakia), the medicine Belkyra is used. In both cases, these are prescription-only medicines that may be administered only by qualified healthcare professionals. Approved use applies exclusively to submental fat (the so-called “double chin”). The FDA explicitly states that safety and effectiveness outside this area have not been established and are not recommended—an important boundary when compared with various “fat-dissolving” cocktail injections promoted online.
How the procedure works and how many sessions are typically needed
After assessing the anatomy, the physician marks a grid of injection points (typically 1 cm apart) and injects a small amount of solution at each point. One session may include up to 50 micro-injections with a total volume of up to 10 ml, and dosing is adjusted to the size of the fat pad. At least 4 weeks is typically left between sessions, and up to 6 sessions may be administered in total; however, many patients notice visible improvement after 2–4 visits. Swelling, tenderness, a feeling of firmness/tightness, or temporary numbness are common after the procedure and usually resolve over days to weeks.
Results and evidence from clinical studies
The strongest evidence comes from double-blind, placebo-controlled studies of deoxycholate (ATX-101). In the well-known REFINE-1 study, 12 weeks after the last treatment, at least a 1-grade improvement on the combined physician/patient assessment was achieved by 70% of treated participants versus 18.6% with placebo; objective MRI measurements also confirmed a significantly higher responder rate in favor of treatment. Reported adverse effects were mostly local and transient; less commonly, temporary weakness of a branch of the facial nerve occurred, which in the study usually resolved without sequelae.
Who is a suitable candidate (and who is not)
The ideal candidate has a localized fat pad under the chin without marked skin laxity or dominant platysmal bands, because once the fat is reduced, excess skin may look aesthetically worse. Before treatment, the physician should rule out other causes of fullness (e.g., an enlarged thyroid gland or lymph nodes) and consider any prior procedures in the neck area that may alter anatomy. The method is not intended for people with an infection at the injection site, for children, and it is used cautiously during pregnancy or in patients with bleeding/clotting disorders.
Risks and possible complications
In addition to typical reactions such as swelling, bruising, pain, redness, and firmness, less common but more serious complications include temporary paralysis of the marginal mandibular branch of the facial nerve causing an asymmetric smile, difficulty swallowing, alopecia at the injection site, or—if the injection is too superficial—skin ulceration and necrosis. Risk minimization depends on correct indication, proper injection technique, and respecting “no-go” zones near sensitive structures. This is also why treatment should be performed only by a trained medical professional, not by cosmetic salons without medical supervision.
Why (not) to inject deoxycholate elsewhere on the body
In practice, you may come across offers of “injectable lipolysis” for the flanks, abdomen, arms, or knees, but it is important to distinguish regulated medicines from unapproved mixtures. In 2023, the FDA warned about serious adverse events following unapproved injections using various cocktail formulations (e.g., Aqualyx, Lipodissolve, Lipo Lab, Kabelline), often containing phosphatidylcholine and deoxycholate in unregistered combinations. For these products, neither safety nor effectiveness has been evaluated; reported outcomes include scarring, infections, skin deformities, or painful nodules. By contrast, approved deoxycholate use is limited to the submental area, where it has undergone formal risk–benefit evaluation and follows a clear dosing and technical protocol.
Recovery and durability of the effect
Swelling is usually most pronounced after the first session and may last several days, so many patients schedule the procedure toward the end of the week. Common recommendations include cooling the area, wearing loose clothing around the neck, and temporarily limiting intense activities for the first 24–48 hours. Deoxycholate destroys cells that cannot store fat again, so the effect is long-lasting with stable weight. However, with weight fluctuations, contours can change even in the treated area, since surrounding fatty tissue responds to weight gain and loss.
Regulatory status: Kybella vs. Belkyra (including Slovakia)
In the U.S., the approved medicine is marketed as Kybella; in the EU, Belkyra is used. The European Medicines Agency lists deoxycholate (Belkyra) as a nationally authorised medicinal product in multiple EU countries, including Slovakia. This means a healthcare facility can legally use a registered product with clearly defined indications, dosing, and safety measures. This also helps you distinguish a reputable clinic using a registered medicine from unverified “lipolytic” cocktails without regulatory oversight.
Alternatives to injectable lipolysis
Alternatives include non-surgical fat-reduction technologies (e.g., cryolipolysis) or surgical liposuction. Cryolipolysis can be suitable for larger areas with a consistent fat thickness, but it comes with a different risk profile and requires applicators of specific shapes. Liposuction remains the most predictable option for larger volumes and contouring possibilities, but it is invasive and requires a longer recovery. In the submental area, where the goal is mainly subtle contour refinement, deoxycholate is a popular choice because of its minimally invasive profile—always after an individualized assessment.
Video: What Kybella under-chin injections look like (educational demonstration)
This video shows branded deoxycholate injections for the “double chin” area in a real clinical setting (in English).
Sources
- KYBELLA® (deoxycholic acid) injection — U.S. Prescribing Information (FDA). https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206333s005lbl.pdf (accessdata.fda.gov)
- Jones DH et al. REFINE-1, a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial With ATX-101. Dermatol Surg. 2016;42(1):38–49. PubMed: https://pubmed.ncbi.nlm.nih.gov/26673433/ (PubMed)
- European Medicines Agency — Deoxycholic acid (Belkyra): List of nationally authorised medicinal products (including Slovakia). https://www.ema.europa.eu/en/documents/psusa/deoxycholic-acid-list-nationally-authorised-medicinal-products-psusa00010525202104_en.pdf (European Medicines Agency (EMA))
- FDA Health Playbook: Using Fat-Dissolving Injections That Are Not FDA Approved Can Be Harmful (Aqualyx, Lipodissolve, etc.). https://www.fda.gov/drugs/buying-using-medicine-safely/using-fat-dissolving-injections-are-not-fda-approved-can-be-harmful (U.S. Food and Drug Administration)
Jana
I like turning curiosity into words, and writing articles is my way of capturing ideas before they slip away — and sharing them with anyone who feels like reading.
